Page last updated: 2024-09-02

ecteinascidin 743 and pyrazines

ecteinascidin 743 has been researched along with pyrazines in 4 studies

Compound Research Comparison

Studies (ecteinascidin 743)	Trials (ecteinascidin 743)	Recent Studies (post-2010) (ecteinascidin 743)	Studies (pyrazines)	Trials (pyrazines)	Recent Studies (post-2010) (pyrazines)
660	102	404	12,165	1,373	5,747

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adams, J; Elliott, PJ	1
Bailly, C; Lansiaux, A	1
von Mehren, M	1
Amaral, AT; D'Incalci, M; De Alava, E; Di Giandomenico, S; Frapolli, R; Garofalo, C; Hassan, AB; Malaguarnera, R; Manara, MC; Mancarella, C; Ordóñez, JL; Picci, P; Scotlandi, K; Sevillano, V; Uboldi, S	1

Reviews

2 review(s) available for ecteinascidin 743 and pyrazines

Article	Year
New agents in cancer clinical trials. Oncogene, 2000, Dec-27, Volume: 19, Issue:56 Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Isoquinolines; Lactams, Macrocyclic; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Rifabutin; Stilbenes; Tetrahydrofolates; Tetrahydroisoquinolines; Trabectedin; Vorinostat	2000
New therapeutic strategies for soft tissue sarcomas. Current treatment options in oncology, 2003, Volume: 4, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin	2003

Article

Year

New agents in cancer clinical trials.

Oncogene, 2000, Dec-27, Volume: 19, Issue:56

Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Isoquinolines; Lactams, Macrocyclic; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Rifabutin; Stilbenes; Tetrahydrofolates; Tetrahydroisoquinolines; Trabectedin; Vorinostat

2000

New therapeutic strategies for soft tissue sarcomas.

Current treatment options in oncology, 2003, Volume: 4, Issue:6

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin

2003

Other Studies

2 other study(ies) available for ecteinascidin 743 and pyrazines

Article	Year
[Perspectives on the oncologist pharmacopoeia]. Bulletin du cancer, 2003, Volume: 90, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin	2003
Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-15, Volume: 21, Issue:6 Topics: 12E7 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Caspase 7; Cell Line, Tumor; Dioxoles; DNA Damage; DNA Repair; DNA-Binding Proteins; Doxorubicin; Female; Humans; Imidazoles; Insulin-Like Growth Factor I; Mice; Mice, Nude; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Protein c-fli-1; Pyrazines; Receptor, IGF Type 1; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin	2015

Article

Year

[Perspectives on the oncologist pharmacopoeia].

Bulletin du cancer, 2003, Volume: 90, Issue:1

Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin

2003

Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-15, Volume: 21, Issue:6

Topics: 12E7 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Caspase 7; Cell Line, Tumor; Dioxoles; DNA Damage; DNA Repair; DNA-Binding Proteins; Doxorubicin; Female; Humans; Imidazoles; Insulin-Like Growth Factor I; Mice; Mice, Nude; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Protein c-fli-1; Pyrazines; Receptor, IGF Type 1; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin

2015